Disadvantages of Continuing Bisphosphonates Beyond 5 Years

Specific Long-Term Harms

• The primary disadvantages of continuing bisphosphonates beyond 5 years are increased risks of osteonecrosis of the jaw and atypical femoral fractures, with observational data showing these rare but serious adverse events occur more frequently with longer treatment duration, particularly after 5 years of therapy 1, 2
• Incidence of osteonecrosis of the jaw increases with duration, with risk escalating with extended treatment beyond 5 years 3
• The most consistent risk factor for osteonecrosis of the jaw is recent dental surgery or extraction 4
• Monthly IV bisphosphonate schedules show higher rates of osteonecrosis of the jaw than osteoporosis dosing schedules, which have 0% to 1% incidence 3
• Risk of atypical femoral fractures increases with cumulative dose and duration, with these subtrochanteric fractures occurring despite treatment intended to prevent fractures 1, 2
• Observational studies demonstrate higher risk of atypical femoral fractures after longer treatment duration, particularly beyond 5 years 1, 2

Limited Additional Fracture Benefit

• Extending treatment beyond 5 years reduces vertebral fractures but NOT other fracture types 1, 2
• This limited benefit profile must be weighed against increasing harm risks 1, 2

Guideline-Based Recommendations

• The American College of Physicians explicitly states that clinicians should consider stopping bisphosphonate treatment after 5 years unless the patient has strong indication for continuation 1, 2
• High-risk patients may warrant continuation to 7-10 years 5, 6
• Moderate-risk patients should generally stop at 5 years with reassessment 1, 2
• Patients who fracture after ≥18 months of bisphosphonate therapy or experience significant bone density decline should switch to another medication class rather than continue bisphosphonates 5, 6

Clinical Pitfalls to Avoid

• The decision to continue beyond 5 years must be individualized based on fracture risk, medication type, and half-life in bone 1, 2
• Simply continuing indefinitely without reassessing risk-benefit is inappropriate 1, 2
• All patients on long-term bisphosphonates require oral examination and good oral hygiene 3
• Invasive dental procedures should be completed before initiating therapy or carefully timed during treatment 3, 4

Management of Bisphosphonates Prior to Dental Implants

Risk Stratification and Management

• Patients who require dental work should have this completed and be given time to heal before bisphosphonate initiation, as recommended by guidelines from the American Association of Oral and Maxillofacial Surgeons, to prevent ONJ complications 7, 8
• The risk of ONJ is increased in patients with recent dental surgery or extraction, and clinical judgment should guide the management plan based on individual benefit/risk assessment, with consideration of the patient's fracture risk and ONJ risk 7, 8

Clinical Algorithm for Decision-Making

• Not yet on bisphosphonates: Complete all dental implant work first, allow healing, then initiate therapy, to minimize the risk of ONJ, as supported by evidence from Clinical Infectious Diseases 7, 8
• The overall incidence of ONJ remains very rare (<1 case per 100,000 person-years), but the severity of complications justifies preventive measures, including optimizing oral hygiene and using prophylactic antibiotics, as recommended by guidelines from relevant medical societies 7, 8

Guidelines for Discontinuing Bisphosphonate Therapy after 5 Years

Timing of Reassessment

• Clinicians should reassess bisphosphonate therapy after 5 years of continuous treatment and consider stopping it unless a strong indication for continuation exists; the decision should be based on an individualized fracture‑risk assessment rather than chronological age. 9

Risk‑Stratified Approach after 5 Years

• High‑risk patients (e.g., those with a prior fracture occurring during therapy or with a rapid bone‑density loss of ≥10 % per year) should continue bisphosphonate treatment to reach a total duration of 7–10 years. 10, 11
• Moderate‑risk patients (stable bone density and no fractures) may be offered a drug holiday of 1–2 years with close monitoring, while low‑risk patients (no fractures and stable or improved bone density) can discontinue therapy altogether. (These risk categories are derived from the 5‑year reassessment framework; specific citation for the categorisation is the same as the overall 5‑year recommendation.) 9

Long‑Term Harms of Prolonged Use

• Extending bisphosphonate therapy beyond 5 years is associated with an increased incidence of osteonecrosis of the jaw and atypical femoral fractures, while providing no additional benefit for non‑vertebral fracture reduction. 9

Management of Treatment Failure

• If a patient experiences a new fracture after ≥18 months of bisphosphonate therapy or demonstrates ≥10 % bone‑density loss per year, the recommended action is to switch to an alternative anti‑osteoporotic agent (e.g., teriparatide or denosumab) rather than persisting with or changing to another bisphosphonate. 10, 11

Special Consideration for Chronic Glucocorticoid Users

• Patients receiving chronic glucocorticoid therapy who remain at moderate‑to‑high fracture risk should continue active anti‑osteoporotic treatment beyond 5 years—either by maintaining oral bisphosphonate therapy, switching to an intravenous bisphosphonate, or transitioning to another drug class. 10, 11